BACK TO OPTIONS
Kidney
Newsletter
Keeping you up to date with the latest exciting advances and discussions in nephrology
Key publications
See below for a concise list and journal links to the cornerstone and latest publications relating to your disease area.
CKD-MBD
Cozzolino M, et al. Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis. Clin Kidney J 2021;14:2437–43
Bover J, et al. Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-dialysis chronic kidney disease: a meta-analysis. Clin Kidney J 2021;14:2177–86
Wetmore JB, et al. Testing patterns for CKD-MBD abnormalities in a sample US population. Kidney Int Rep 2021;6:1141–50
Molina P, et al. Disorders in bone-mineral parameters and the risk of death in persons with chronic kidney disease stages 4 and 5: the PECERA study. J Nephrol 2021;34:1189–99
Geng S, et al. Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease. Osteoporos Int 2019;30:2019–25
Xu Y, et al. Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease. Clin Kidney J 2021;sfab006 Bozic M, et al. Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrol Dial Transplant 2021;gfab184 Tabibzadeh N, et al. The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation. Nephrol Dial Transplant 2021;36:160–9 Ketteler M, Ambühl P. Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease.J Nephrol 2021; doi: 10.1007/
s40420-021-01082-2
CKD-aP
Ahdoot RS, et al. Novel approach to unpleasant symptom clusters surrounding pruritus in patients with chronic kidney disease and on dialysis therapy. Curr Opin Nephrol Hypertens 2022;31:63–71
You AS, et al. Dialysis symptom index burden and symptom clusters in a prospective cohort of dialysis patients. J Nephrol 2022; doi:10.1007/s40620-022-01313-0 Kim D, Pollock C. Epidemiology and burden of chronic kidney disease-associated pruritus. Clin Kidney J
2021;14:i1–i7 Lipman ZM, et al. Clinical management of chronic kidney disease-associated pruritus: current treatment options and future approaches. Clin Kidney J 2021;14:i16–i22 Manenti L, Leuci E. Do you feel itchy? A guide towards diagnosis and measurement of chronic kidney disease-associated pruritus in dialysis patients. Clin Kidney J 2021;14:i8–i15 Schricker S, Kimmel M. Unravelling the pathophysiology of chronic kidney disease-associated pruritus. Clin Kidney J 2021;14:i23–i31 Verduzco HA, et al. CKD-associated pruritus: new insights into diagnosis, pathogenesis, and management. Kidney Int Rep 2020;5:1387–402 Rayner HC, et al. International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis. Clin J Am Soc Nephrol 2017;12:2000–7 Ramakrishnan K, et al. Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms. Int J Nephrol Renovasc Dis 2014;7:1–12 Sukul N, et al. Self-reported pruritus and clinical, dialysis-related, and patient-reported outcomes in hemodialysis patients. Kidney Med 2020;3:42–53
AAV
Grayson PC, et al. American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis 2022;81:309–14
Robson JC, et al. American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis 2022;81:315–20
Suppiah R, et al. American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis 2022;81:321–6
Rutherford PA, Götte D. Anti-neutrophil cytoplasmic autoantibody-associated vasculitis: from diagnosis to outcomes. EMJ Nephrol 2020;8[Suppl 4]:2–16
Jennette JC, Nachman PH. ANCA glomerulonephritis and vasculitis. Clin J Am Soc Nephrol 2017;12:1680–91
Flossmann O, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488–94
Little MA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010;69:1036−43
HK
Muhlestein JB, et al. Real-world clinical burden and economic assessment associated with hyperkalaemia in a large integrated healthcare system: a retrospective analysis. BMC Prim Care 2022;23:65
Epstein M, et al. Hyperkalemia with mineralocorticoid receptor antagonist use in people with CKD. Clin J Am Soc Nephrology 2022;17:455–7 Riccio E, et al. RAAS inhibitor prescription and hyperkalemia event in patients with chronic kidney disease: a single-center retrospective study. Front Cardiovasc Med 2022;9:824095 Leon JS, et al. Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study. Am J Kid Dis 2022;S0272-6386(22)00034-8 Muhlestein JB, et al. Frequency and clinical impact of hyperkalaemia within a large, modern, real-world heart failure population. ESC Heart Fail 2021;8:691–6 Bem D, et al. The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review. Ren Fail 2021;43:241–54
References and footnotes
FOOTNOTES
AAV, anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; CKD-aP, chronic kidney disease-associated pruritus; CKD-MBD, chronic kidney disease-mineral bone disorder; HK, hyperkalaemia.